Too Old, Too Late, Too Risky? Plastic Surgery after Menopause

Episode summary

This episode separates chronological age from the factors that shape surgical planning: health, mobility, weight stability, tissue quality, the proposed operation, and clot risk. Dr. Smith discusses studies of older cosmetic-surgery patients while identifying abdominoplasty as an important exception within that discussion.

The recording explains how changes around menopause can affect skin recoil, scar maturation, breast tissue, and the amount of support available for a lift or implant. It connects those considerations to auto-augmentation mastopexy and to the longer-term responsibilities of choosing implants. Slower scar maturation is distinguished from a claim that the final scar must be worse.

A substantial part of the episode concerns hormone therapy. Dr. Smith distinguishes oral from transdermal estrogen, explains his own approach before tummy tuck, and explicitly describes where his preference is a judgment call rather than a universally required rule. Individual risk assessment and clot prevention remain central regardless of the hormone decision. This discussion is a basis for questions with the surgeon and prescribing clinician, not an instruction to change medication independently.

The episode also distinguishes subcutaneous fat, which liposuction can address, from visceral fat around organs. It closes with planning around the stage of the menopausal transition and the stability of weight and hormone treatment, rather than using one age cutoff for every patient.

Questions this episode answers

Does age alone determine whether someone can have plastic surgery?

The episode argues for assessing health, function, the procedure, and individual risk rather than relying on age alone. It separately discusses the risk findings for tummy tuck.

How can menopause affect breast surgery planning?

Dr. Smith discusses tissue quality, upper-pole fullness, support for an implant, and whether rearranging the patient’s own tissue may better serve the intended result.

Why does the episode distinguish an estrogen pill from a patch?

It explains their different routes through the body and the relevance of those routes to the clot-risk discussion. Dr. Smith’s own practice treats them differently, within an individualized surgical assessment.

Does every patient need the same hormone plan?

No. The recording explicitly distinguishes the surgeon’s practice preference from a universal requirement and makes the operation and individual clot risk part of the decision.

Can liposuction remove the fat around internal organs?

No. The episode distinguishes fat beneath the skin from visceral fat and explains that liposuction addresses the former.

Original show notes

Board-certified New York City plastic surgeon Dr. Darren Smith examines what menopause actually changes about surgery and what it doesn't — including why he asks most tummy tuck patients to stop hormone therapy, while being candid that the evidence does not require him to.

What you'll hear in this episode

📊 The Age Proxy

Why a study of roughly 184,000 cosmetic procedures found no meaningful difference in complications between patients over 65 and everyone younger — and why age is standing in for the variables that actually predict outcomes.

⚠️ The Tummy Tuck Exception

The single operation where older patients did fare worse, and how a separate analysis of the same database independently identified age 55 as a risk factor within that procedure specifically.

⏳ The Estrogen Clock

Why the collagen loss that matters is measured from menopause rather than from your birthday, and how two women of the same age can arrive with entirely different tissue.

🩹 The Scar Distinction

What the healing evidence actually supports — slower scar maturation — and the claim it does not support: that the scars end up worse.

⬆️ The Upper Pole Problem

Why a standard mastopexy in this population often fails to hold upper pole fullness, why what goes up must come down, and when auto-augmentation becomes the better answer.

🔄 The Lifetime Device Question

Why choosing implants at 55 is really a decision about 65 and 75, and how that reframes the implant conversation after menopause.

💊 The Pill-Patch Divide

The one distinction that changes the hormone answer completely: why oral estrogen passes through the liver and nudges the clotting system, while transdermal estrogen appears not to — even in women with existing risk factors.

📅 The Four-Week Rule

Why stopping hormones the week before surgery is theater, how long the effect actually takes to clear, and exactly what Dr. Smith does in his own practice.

⚖️ Redistribution, Not Willpower

Why the midlife shift toward the middle is hormonal rather than a failure of discipline, and the hard limit on what liposuction can and cannot reach.

🧬 What Actually Settles

Why “wait until things settle” describes something real — the breast's fat-to-stroma balance stops shifting in the mid-fifties — and why the glandular tissue keeps changing after that.

🔍 Judgment Versus Evidence

Why you should want a surgeon who can tell you which of their rules are proven and which are judgment calls, and why uniform confidence across claims of very different quality is not expertise.

🔗 Resources and links

📍 Considering plastic surgery and wondering how menopause factors in? Schedule a consultation with Dr. Smith at the Ritz Tower, Park Avenue and East 57th Street, Manhattan.

🎧 The earlier episode referenced in this discussion: The Natural Lift: Everything You Need to Know About Auto-Augmentation Mastopexy.

🎙️ Plastics & Peptides, Dr. Smith's podcast with longevity medicine specialist Dr. Amanda Kahn — listen on Apple Podcasts or Spotify.

📚 References

Yeslev M, et al. Safety of cosmetic procedures in elderly and octogenarian patients. Aesthetic Surgery Journal. 2015;35(7):864-873. https://doi.org/10.1093/asj/sjv053

Winocour J, et al. Abdominoplasty: risk factors, complication rates, and safety of combined procedures. Plastic and Reconstructive Surgery. 2015;136(5):597e-606e. https://doi.org/10.1097/PRS.0000000000001700

Zomer HD, Cooke PS. Targeting estrogen signaling and biosynthesis for aged skin repair. Frontiers in Physiology. 2023;14:1281071. https://doi.org/10.3389/fphys.2023.1281071

Wilkinson HN, Hardman MJ. The role of estrogen in cutaneous aging and repair. Maturitas. 2017;103:60-64. https://doi.org/10.1016/j.maturitas.2017.06.026

Mittal P, et al. Venous thromboembolism (VTE) prophylaxis after abdominoplasty and liposuction: a review of the literature. Aesthetic Plastic Surgery. 2020;44(2):473-482. https://doi.org/10.1007/s00266-019-01576-2

Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. https://doi.org/10.1136/bmj.k4810

Mohammed K, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2015;100(11):4012-4020. https://doi.org/10.1210/jc.2015-2237

Committee on Practice Bulletins — Gynecology. Prevention of venous thromboembolism in gynecologic surgery: ACOG Practice Bulletin No. 232. Obstetrics and Gynecology. 2021;138(1):e1-e15. https://doi.org/10.1097/AOG.0000000000004445

Skeith L, Bates SM. Sex hormone influences on venous thrombotic and cardiovascular risk. New England Journal of Medicine. 2026;394(15):1514-1528. https://doi.org/10.1056/NEJMra2202438

Abouharb ALZ, et al. Withholding of hormone replacement therapy prior to total joint arthroplasty surgery to reduce the risk of postoperative thromboembolic events: is it justified? A systematic review of clinical practice guidelines. Journal of Arthroplasty. 2024;39(2):541-548.e24. https://doi.org/10.1016/j.arth.2023.08.061

Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. https://doi.org/10.1172/jci.insight.124865

El Khoudary SR, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention. A scientific statement from the American Heart Association. Circulation. 2020;142(25):e506-e532. https://doi.org/10.1161/CIR.0000000000000912

Sandhu R, Chollet-Hinton L, Kirk EL, Midkiff B, Troester MA. Digital histologic analysis reveals morphometric patterns of age-related involution in breast epithelium and stroma. Human Pathology. 2016;48:60-68. https://doi.org/10.1016/j.humpath.2015.09.031

[00:00] Almost every woman I meet in her 50s has been told two things about surgery, that she's probably too old for it, and that she'll have to stop her hormones to have it. The first one is just wrong, and the data has been clear on that for a decade. The second one is more complicated, because I do ask most of my tummy tuck patients to stop their hormones. And the honest answer is that the evidence doesn't require me to. So today, I want to show you what menopause actually does to your tissue. Walk you through how that changes the operation I plan, and tell you exactly how I make the hormone decision, including the one distinction that flips the answer completely and almost nobody explains to patients before surgery. I'm board-certified New York City plastic surgeon Dr. Darren Smith, and this is Plastic Surgery Before and After, your source for the real deal about plastic surgery procedures, news about trends in aesthetic medicine, and candid sessions with industry insiders. We hope you enjoy today's episode.

[01:08] Let's start with the age question, because it's the one that's actually settled, and it takes two minutes. Researchers looked at roughly 184,000 cosmetic procedures, and compared the patients over 65 with everyone younger, average age about 39. They were looking for the age effect that everybody assumes must be there. They didn't find it. Complication rates weren't meaningfully different, and they ran the same comparison for the patients over 80 and got the same answer. Now, that doesn't mean age is irrelevant to your body. What it means is that age by itself is a poor predictor of how an operation goes, because it's standing in for the things that actually predict it. Diabetes, what your weight has been doing, whether you smoke, how well you move.

[01:52] A 62-year-old who walks four miles a day is a better surgical candidate than a 45-year-old who smokes. That's not a nice sentiment. That's what the data says. There was one exception, one operation where the older patients did do worse. It was the tummy tuck. And that isn't a quirk of a single study. A separate analysis of the same database went looking specifically within abdominoplasty and found that being over 55 was an independent risk factor, not for cosmetic surgery in general, but for that operation in particular. Two different ways of cutting the data, and the same operation gets flagged both times. Hold on to that, because it comes back, and it isn't a coincidence. So, if age isn't the variable, what is? It's estrogen. And the connection runs through collagen. Estrogen is one of the things that keeps your skin building collagen, and it also keeps the enzymes that break collagen down in check.

[02:48] It's working both sides of that equation. So, when estrogen drops off at menopause, the balance tips in both directions at once. You're producing less and breaking down more. The skin gets thinner and loses its recoil. Which means the important part isn't how much collagen you lose. It's when the clock starts. Your skin loses roughly a third of its collagen in the first five years after menopause. Then, the loss slows way down. So, the number that matters isn't your age. It's how long it's been since menopause. Which means two women who are both 58 can have completely different skin. The woman who went through menopause at 44 has been at this for 14 years. The woman who went through it at 53 has been at it for 5.

[03:32] Same age on the chart, different tissue on the table. And planning as though they're the same patient is a reliable way to produce a result that doesn't match what you promised. Healing works the same way. After menopause, wounds close more slowly and lay down less collagen along the way. And when researchers have tried to separate general aging from estrogen specifically, the evidence points at estrogen. I want to be careful how you hear that, because I've watched patients take it badly. What the data supports is that your scars take longer to settle. It does not support the claim that they end up worse. Those are different statements.

[04:10] If you're a year out and still watching a scar mature, that may be completely normal for where you are hormonally. It is not evidence that something went wrong. So what does that tissue change actually do to an operation? Thinner skin with less recoil re-drapes differently. It tolerates less tension. It sets a lower ceiling on how much I can safely remove and still close the way I want to. None of that makes the operation harder to do. It makes it a different operation to plan. The breast shows this better than anything else, so let me use it. Through the years around menopause, dense glandular tissue gradually gives way to fat. The breast gets softer, less dense, and there's simply less tissue to work with than there was. A couple of things follow from that. First, a lift on its own will often leave less upper pole fullness in this population than the same lift would in a younger patient. Unless specific tissue rearrangement maneuvers are performed, well, what goes up must come down. And in this population, the tissue repositioning done as part of most standard mastopexies will not resist gravity effectively enough to maintain an aesthetic upper pole.

[05:21] Which is why auto-augmentation, using your own tissue to restore that fullness, comes up so much more often in this conversation. I did a whole episode on auto-augmentation mastopexy, and if this is where you are, it's worth going back to. Second, when I do use implants here, I go smaller. Not because smaller is fashionable, which they do happen to be right now, but because there's less soft tissue to support and camouflage the device. In borderline cases, I'll consider a mesh for additional support. And one more thing on implants that we have to discuss. They aren't lifetime devices. Choosing them at 55 commits you to questions that show up at 65 and 75.

[06:02] That's not an argument against implants. I place them regularly and I believe in them. It's an argument for choosing them with a clear view of what you're signing up for. Quick caution before I move on. Sagging is associated with menopause. I'm not going to tell you estrogen loss causes it, because that's a cleaner story than the evidence supports. Weight change, pregnancy, breastfeeding, how large your breasts were to begin with, plain genetics, they all contribute. Menopause is part of that picture. It isn't the whole picture. Which brings us back to the tummy tuck, and why it was the exception in that safety data. Of every cosmetic operation we do, the tummy tuck carries the highest risk of blood clots.

[06:44] That's one of the most serious complications in aesthetic surgery, and abdominoplasty sits at the top of the list. Hormone therapy adds to clot risk. That's well established. So a lot of surgeons, me included, ask patients to stop before this operation. But the guidelines don't require it. The major professional bodies don't say stop hormones before surgery. They say assess each patient individually and decide together. And a good deal of the recent literature argues for close to the opposite of what I do. Keeping women on their hormones and managing the clot risk directly, on the grounds that stopping carries real costs. Which it does. You lose sleep, you lose temperature regulation, and you go into a recovery that's already hard with your symptoms back.

[07:30] That's a genuine disagreement among careful people, and I'm not going to flatten it just because I've landed on one side. So let me tell you why I've landed where I have. It comes down to the fact that the two risks aren't symmetric. Four weeks of your symptoms coming back is genuinely miserable, and it is completely reversible. You restart and you're back where you were. A clot after a tummy tuck is not reversible in the same way. Most are treatable, some cause lasting problems, and a small number are catastrophic. When one side of a decision can be undone and the other side can't, I lean toward the one that can. That's a judgment about which mistake I'd rather make.

[08:10] It isn't a finding I can point you to in a study, and I'd rather say so. Now here's the distinction that changes the answer, and it's the thing I most want you to take out of this episode. It matters enormously whether your estrogen is a pill or a patch. Estrogen you swallow goes through your liver first. On the way through, it nudges your clotting system in exactly the direction we're worried about. Estrogen that goes through your skin largely bypasses that process. And in the best evidence we have, patches don't appear to raise clot risk the way pills do, including in women who already carry other risk factors, which is precisely the group where you'd expect a reassuring finding to fall apart. So a patient on a patch and a patient on a pill are not the same conversation. Treating them as though they are is sloppy thinking dressed up as caution.

[09:00] Timing is the other piece people get wrong. The effect of hormones on your clotting system doesn't switch off when you stop taking them. It takes weeks to resolve. Which means stopping the week before your operation is theater. It looks like caution and accomplishes almost nothing. Let me be unambiguous about the part that doesn't vary. Clot prevention happens for every patient, regardless of what we decide about hormones. That means a real individual risk assessment and a prevention plan matched to you, including a dose appropriate to your body size, because standard dosing in a larger patient is under treatment, and that's a real way people get hurt.

[09:37] The hormone question is the part that's debatable. Preventing clots is not. So here's what I actually do, offered as my practice and not as a standard. One. Hormones stop four weeks before a tummy tuck. Four weeks, not four days, because four days accomplishes nothing given how long the effect takes to clear. Two. Patches are the exception. I don't stop those. Three. Every patient gets an individual clot risk assessment and a prevention plan, whatever we decided about the hormones. Is that the only defensible position? No, it's a defensible position. It isn't mandated, and I'd rather tell you that than hand you a judgment call dressed up as settled science. What I'll say with more confidence is this.

[10:24] A surgeon who holds your hormones but doesn't properly assess your clot risk has worried about the wrong thing. Let me turn to something that comes up in nearly every consultation with a woman at this stage. Menopause doesn't really add weight. It moves it. The weight gain across midlife tracks pretty closely with just getting older. The redistribution toward the middle. That's the specifically menopausal part. And that sounds like a technicality until you realize it's the difference between a discipline problem and a hormonal one. Women arrive in my office having been told for years, sometimes by people who should know better, that this is about willpower. It isn't. Your body reorganized where it stores fat, on a schedule you had no say in.

[11:08] But I have to be just as straight with you about what liposuction can and can't do here, because this is where a lot of marketing goes wrong. Liposuction removes fat that sits under the skin. It does nothing to the fat around your organs. And the redistribution we're talking about includes a lot of that second kind. So liposuction can genuinely improve your contour. It cannot undo the metabolic change. Anyone telling you otherwise is selling you something. Last thing, timing. Patients ask whether they should wait until things settle down, and they're usually asking because somebody said it to them dismissively. It deserves a better answer than that. Breast tissue is actively remodeling through the menopausal transition, and part of it does stop moving. When researchers measured normal breast tissue directly, not mammograms, the tissue itself, the balance of fat to supporting stroma shifted year after year until about 55, and then it flattened out. So wait until things settle isn't a brush off.

[12:10] It describes something real, and it has a rough endpoint. But I want to be precise about what settles. The glandular tissue doesn't. It keeps changing past 55, and the people who did that work say so plainly. There's no true steady state in there. What stops moving is the fat and stroma balance. That's the part that determines whether a lift or an implant still looks right in five years, which is why it's the part I plan around. The practical version. Stable weight, stable hormones on whatever regimen you and your physician have landed on, and ideally past the thick of the transition rather than in the middle of it. That's not a fixed age. It's a description of the point where your tissue has stopped moving underneath the result, which is when the result is most likely to last. So here's how the decision actually gets made in my practice. In order.

[13:02] 1. First, where are you in the transition? Not, how old are you? If you're in the middle of it, your tissue is still moving, and we talk about whether waiting serves you. 2. Second, what's your tissue quality? That's driven by how long you've been postmenopausal, not by your birthday. It determines how much I can remove, how much tension the closure tolerates, and whether a lift alone gets you where you want to go. 3. Third, what operation are we discussing, and what's your clot risk? If it's a tummy tuck, that risk assessment drives everything downstream, including the hormone conversation. 4. Fourth, and it is deliberately last, pill or patch? Because that single question determines whether I ask you to stop anything at all. That last one being last is the whole point.

[13:54] The hormone question is the one patients arrive worrying about, and it's the one I answer last, because everything above it is what tells me how much the answer even matters. If you start with the hormone question, you've skipped the assessment that should have been driving it. So, to bring it back around. Are you too old? No, that question was answered, and the answer was no. Does menopause change your surgery? Yes, it changes your tissue, your healing, and the plan I build around them. And do you have to stop your hormones? That depends on the operation, and it depends enormously on whether your HRT is a pill or a patch. If you've been told flatly that you'll have to stop, and you're on a patch, that blanket advice may not apply to you. It's worth asking before you accept it. What I'd want you to take from this is a standard for the surgeons you talk to. You want one who can tell you which of their rules are proven, and which are judgment. Because uniform confidence across claims of very different quality isn't expertise. Holding your hormones before a tummy tuck is one of mine that's judgment, and I've given you both my reasoning and the argument against it.

[15:08] The parts that aren't judgment, assessing your risk and preventing clots, happen for everyone either way. If you want to talk through your specific situation, my practice is at the Ritz Tower on Park Avenue and East 57th Street in Manhattan. The link to schedule a consultation is in the description.

Original Captivate episode. Original release date: 2026-08-27. The recording is the source for the transcript, summary and questions above. Original references and production information are preserved in the show notes.

• Tummy tuck planning
• Breast lift options
• Liposuction and its limits
• Related episode: The Natural Lift: Everything You Need to Know About Auto-Augmentation Mastopexy
• Related episode: Life After GLP-1: Completing Your Weight Loss Transformation
• Dr. Smith’s background and training
• Request a consultation in Manhattan